Perspective Therapeutics, Inc. (CATX)Healthcare | Medical Devices | Seattle, United States | NYSE American
3.05 USD
-0.04
(-1.295%) ⇩
(July 14, 2026, 4 p.m.
EDT)
|
Hot Take ↕ | July 11, 2026, 3:26 a.m. EDT
This is a catastrophic long-term investment with zero income potential. The company is hemorrhaging cash, reporting massive losses, and shrinking its revenue base by nearly 78% year-over-year. Despite a 'strong buy' analyst recommendation driven by early clinical trial data, the financial reality is dire: the stock trades at a negative forward P/E, has a negative return on equity, and carries a crushing debt load relative to its tiny market cap. The price history confirms this deterioration, showing a brutal 52% drop over the last nine years, including a 67% crash in the most recent fiscal year. While the recent equity raise suggests management believes in the science, the balance sheet cannot sustain this burn without further dilution or a miracle turnaround. For investors, this is a speculative lottery ticket with no safety margin, making it a firm 'avoid' for any rational portfolio. |
| Model | MAE |
|---|---|
| AutoTheta ✓ | 0.079384 |
| MSTL | 0.125866 |
| AutoETS | 0.129555 |
| AutoARIMA | 0.129557 |
Forecast horizon: 45 days | Selected: AutoTheta
| Forecast Reliability | |
|---|---|
| Score | 40% |
| H-stat | 1.20 |
| Ljung-Box p | 0.000 |
| Jarque-Bera p | 0.246 |
| Excess Kurtosis | -1.21 |
| Attribute | Value |
|---|---|
| Sector | Healthcare |
| Debt to Equity Ratio | 1.218 |
| Revenue per Share | 0.008 |
| Market Cap | 347,840,896 |
| Forward P/E | -2.69 |
| Beta | 1.75 |
| Previous Name | IsoRay, Inc. |
| Website | https://www.perspectivetherapeutics.com |
As of July 11, 2026, 3:26 a.m. EDT: Options activity is extremely thin with negligible open interest across all expirations. Implied volatility is low and flat, indicating a lack of speculative positioning or hedging demand. The market is effectively ignoring the stock for derivatives trading.
| Attribute | Value |
|---|---|
| 52 Week Change | -0.20769233 |
| Address1 | 2,401 Elliott Avenue |
| Address2 | Suite 320 |
| All Time High | 85.0 |
| All Time Low | 1.2 |
| Ask | 0.0 |
| Ask Size | 2,400 |
| Audit Risk | 6 |
| Average Analyst Rating | 1.3 - Strong Buy |
| Average Daily Volume10 Day | 2,238,610 |
| Average Daily Volume3 Month | 1,830,539 |
| Average Volume | 1,830,539 |
| Average Volume10Days | 2,238,610 |
| Beta | 1.746 |
| Bid | 0.0 |
| Bid Size | 1,400 |
| Board Risk | 8 |
| Book Value | 3.047 |
| City | Seattle |
| Compensation As Of Epoch Date | 1,767,139,200 |
| Compensation Risk | 9 |
| Country | United States |
| Crypto Tradeable | 0 |
| Currency | USD |
| Current Price | 3.05 |
| Current Ratio | 8.745 |
| Custom Price Alert Confidence | HIGH |
| Date Short Interest | 1,782,777,600 |
| Day High | 3.145 |
| Day Low | 2.94 |
| Debt To Equity | 1.218 |
| Display Name | Perspective Therapeutics |
| Earnings Timestamp | 1,778,529,600 |
| Earnings Timestamp End | 1,778,529,600 |
| Earnings Timestamp Start | 1,778,529,600 |
| Ebitda | -116,375,000 |
| Ebitda Margins | 0.0 |
| Enterprise To Ebitda | -0.697 |
| Enterprise To Revenue | 131.299 |
| Enterprise Value | 81,142,904 |
| Eps Current Year | -1.13452 |
| Eps Forward | -1.13379 |
| Eps Trailing Twelve Months | -1.41 |
| Esg Populated | 0 |
| Exchange | ASE |
| Exchange Data Delayed By | 0 |
| Exchange Timezone Name | America/New_York |
| Exchange Timezone Short Name | EDT |
| Fifty Day Average | 3.4718 |
| Fifty Day Average Change | -0.42180014 |
| Fifty Day Average Change Percent | -0.12149321 |
| Fifty Two Week Change Percent | -20.769232 |
| Fifty Two Week High | 6.16 |
| Fifty Two Week High Change | -3.11 |
| Fifty Two Week High Change Percent | -0.5048701 |
| Fifty Two Week Low | 1.96 |
| Fifty Two Week Low Change | 1.0899999 |
| Fifty Two Week Low Change Percent | 0.5561224 |
| Fifty Two Week Range | 1.96 - 6.16 |
| Financial Currency | USD |
| First Trade Date Milliseconds | 1,131,633,000,000 |
| Float Shares | 66,423,927 |
| Forward Eps | -1.13379 |
| Forward P E | -2.6900923 |
| Free Cashflow | -58,781,752 |
| Full Exchange Name | NYSE American |
| Full Time Employees | 163 |
| Gmt Off Set Milliseconds | -14,400,000 |
| Governance Epoch Date | 1,782,864,000 |
| Gross Margins | 0.0 |
| Gross Profits | -90,637,000 |
| Has Pre Post Market Data | 1 |
| Held Percent Insiders | 0.10812 |
| Held Percent Institutions | 0.77428 |
| Implied Shares Outstanding | 114,046,197 |
| Industry | Medical Devices |
| Industry Disp | Medical Devices |
| Industry Key | medical-devices |
| Is Earnings Date Estimate | 0 |
| Language | en-US |
| Last Fiscal Year End | 1,767,139,200 |
| Last Split Date | 1,718,582,400 |
| Last Split Factor | 1:10 |
| Long Business Summary | Perspective Therapeutics, Inc., a radiopharmaceutical development company, develops and commercializes precision targeted alpha therapies (TAT) to treat cancer in the United States. It discovers and develops its initial drug candidate VMT-a-NET that is in Phase 1/2a clinical trials for patients with unresectable or metastatic somatostatin receptor type 2 (SSTR2)-expressing neuroendocrine tumors that have not previously received peptide-targeted radiopharmaceutical therapy, such as Lutathera, a beta emitting therapy; VMT01, which is in Phase 1/2a clinical trials for second-line or later treatment of patients with progressive melanocortin 1 receptor (MC1R) positive metastatic melanoma; and PSV359, a targeted alpha therapy targeting fibroblast activation protein alpha. The company also develops Pluvicto, a betaemitting radioligand therapy to treat progressive prostate-specific membrane antigen (PSMA) positive metastatic castration-resistant prostate cancer. It has a clinical trial collaboration agreement with Bristol Myers Squibb to evaluate the safety and tolerability of [212Pb] VMT01 in combination with nivolumab in patients with histologically confirmed melanoma and positive MC1R imaging scans. The company was formerly known as Isoray, Inc. and changed its name to Perspective Therapeutics, Inc. in February 2022. Perspective Therapeutics, Inc. was founded in 2004 and is headquartered in Seattle, Washington. |
| Long Name | Perspective Therapeutics, Inc. |
| Market | us_market |
| Market Cap | 347,840,896 |
| Market State | PRE |
| Max Age | 86,400 |
| Message Board Id | finmb_9934314 |
| Most Recent Quarter | 1,774,915,200 |
| Name Change Date | 2,026-07-15 |
| Net Income To Common | -111,647,000 |
| Next Fiscal Year End | 1,798,675,200 |
| Non Diluted Market Cap | 352,402,748 |
| Number Of Analyst Opinions | 15 |
| Open | 3.09 |
| Operating Cashflow | -92,370,000 |
| Operating Margins | -372.11844 |
| Overall Risk | 6 |
| Payout Ratio | 0.0 |
| Phone | 206 676 0900 |
| Pre Market Change | -0.049999952 |
| Pre Market Change Percent | -1.6393427 |
| Pre Market Price | 3.0 |
| Pre Market Time | 1,784,107,320 |
| Prev Name | IsoRay, Inc. |
| Previous Close | 3.09 |
| Price Eps Current Year | -2.6883614 |
| Price Hint | 4 |
| Price To Book | 1.0009845 |
| Price To Sales Trailing12 Months | 562.84937 |
| Profit Margins | 0.0 |
| Quick Ratio | 8.607 |
| Quote Source Name | Delayed Quote |
| Quote Type | EQUITY |
| Recommendation Key | strong_buy |
| Recommendation Mean | 1.26667 |
| Region | US |
| Regular Market Change | -0.04 |
| Regular Market Change Percent | -1.2945 |
| Regular Market Day High | 3.145 |
| Regular Market Day Low | 2.94 |
| Regular Market Day Range | 2.94 - 3.145 |
| Regular Market Open | 3.09 |
| Regular Market Previous Close | 3.09 |
| Regular Market Price | 3.05 |
| Regular Market Time | 1,784,059,200 |
| Regular Market Volume | 2,810,123 |
| Return On Assets | -0.20268999 |
| Return On Equity | -0.35327 |
| Revenue Growth | -0.778 |
| Revenue Per Share | 0.008 |
| Sand P52 Week Change | 0.20365608 |
| Sector | Healthcare |
| Sector Disp | Healthcare |
| Sector Key | healthcare |
| Share Holder Rights Risk | 1 |
| Shares Outstanding | 114,046,197 |
| Shares Percent Shares Out | 0.1993 |
| Shares Short | 22,724,265 |
| Shares Short Previous Month Date | 1,780,012,800 |
| Shares Short Prior Month | 12,763,401 |
| Short Name | Perspective Therapeutics, Inc. |
| Short Percent Of Float | 0.23799999 |
| Short Ratio | 9.97 |
| Source Interval | 15 |
| State | WA |
| Symbol | CATX |
| Target High Price | 18.0 |
| Target Low Price | 6.0 |
| Target Mean Price | 12.93333 |
| Target Median Price | 13.0 |
| Total Cash | 270,928,992 |
| Total Cash Per Share | 2.376 |
| Total Debt | 4,231,000 |
| Total Revenue | 618,000 |
| Tradeable | 0 |
| Trailing Annual Dividend Rate | 0.0 |
| Trailing Annual Dividend Yield | 0.0 |
| Trailing Eps | -1.41 |
| Trailing Peg Ratio | None |
| Triggerable | 1 |
| Two Hundred Day Average | 3.58975 |
| Two Hundred Day Average Change | -0.5397501 |
| Two Hundred Day Average Change Percent | -0.15035869 |
| Type Disp | Equity |
| Volume | 2,810,123 |
| Website | https://www.perspectivetherapeutics.com |
| Zip | 98,121 |